Pfizer touts bladder cancer results as first advancement for some patients 'in decades'

Pfizer said its experimental anti-PD-1 drug bested the current standard of care in a type of bladder cancer where progress has been limited. Its therapy, called sasanlimab, significantly prolonged patients’ event-free survival in combination with ...